Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
24,141,356
-
Share change
-
-796,169
-
Total reported value
-
$42,026,786
-
Put/Call ratio
-
170%
-
Price per share
-
$1.70
-
Number of holders
-
72
-
Value change
-
-$4,185,117
-
Number of buys
-
35
-
Number of sells
-
42
Institutional Holders of BELLICUM PHARMACEUTICALS INC - COM (BLCM) as of Q2 2019
As of 30 Jun 2019,
BELLICUM PHARMACEUTICALS INC - COM (BLCM) was held by
72 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
24,141,356 shares.
The largest 10 holders included
JPMORGAN CHASE & CO, BAKER BROS. ADVISORS LP, Nikko Asset Management Americas, Inc., Sumitomo Mitsui Trust Holdings, Inc., VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, ARK Investment Management LLC, BlackRock Inc., FRAZIER MANAGEMENT LLC, and GOLDMAN SACHS GROUP INC.
This page lists
72
institutional shareholders reporting positions in this security
for the Q2 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.